Clinical Trial for Non-inferiority and Safety of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in Patients With Hematologic Malignancies Who Require Prophylactic Hepatitis B Antiviral Treatment

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

December 31, 2026

Conditions

Patients With Malignant Blood Disease Requiring Hepatitis B Antiviral Medication

Interventions

DRUG

Vemlidy

1 tablet once a day, oral administration

DRUG

Virreal

1 tablet once a day, oral administration

All Listed Sponsors

lead

Yonsei University

OTHER